(Total Views: 664)
Posted On: 12/10/2020 1:01:05 PM
Post# of 153908
And now for something completely different....for those that follow FDA policies and procedures that affect CytoDyn drug applications.
More info at:
https://www.fda.gov/industry/prescription-dru...-2023-2027
Quote:
In August 2017, the FDA Reauthorization Act of 2017 (FDARA) was enacted, which renewed the prescription drug user fee program (PDUFA) for a sixth time. The current legislative authority for PDUFA VI expires in September 2022. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years.
Information related to FDA’s preparation for the seventh reauthorization of PDUFA will be hosted here on this page as it becomes available.
More info at:
https://www.fda.gov/industry/prescription-dru...-2023-2027
(0)
(0)
